Causal AI & Digital Twins: Transforming Drug Discovery

Published Date: 08/07/2024

Aitia's patient-data-derived Gemini digital twins are uncovering hidden genetic and molecular mechanisms driving human disease, transforming the field of drug discovery and development.

Aitia's CEO Colin Hill had a vision 25 years ago to use technology to reverse-engineer biological circuitry directly from genomic and molecular data from patient tissue. Today, Aitia is positioned to realize its vision, using causal AI and digital twins to discover novel drug targets and biological mechanisms.

Aitia's approach fundamentally differs from previous methods of drug discovery and AI techniques. The company has established a critical mass of data partnerships in neurodegeneration and oncology, accessing datasets that include DNA sequence variation, gene expression, and proteomics data, and quantitative clinical outcomes for thousands of patients.

Using causal AI and cloud computing, Aitia is turning the data into Gemini digital twins that reverse-engineer the hidden 95% of human biological circuitry. The digital twins allow for accurate simulation of gene and protein knockdowns at the individual patient level, enabling the discovery and genetic validation of drug targets and biological mechanisms that would otherwise remain hidden for decades.

Aitia has validated the technology via multiple patient cohorts, in vitro and in vivo experiments, and clinical studies, resulting in over 70 peer-reviewed articles and abstracts. Pharmaceutical external research and development groups have recognized the power of the platform, leading Aitia to successfully partner with 17 of the top 20 pharma companies.

Aitia is now an AI-powered drug discovery and development organization, having evolved from a provider of AI technology. The company is focusing on neurodegenerative diseases, with programs in Alzheimer's, Parkinson's, Huntington's, and amyotrophic lateral sclerosis (ALS).

Aitia's digital twins successfully predict clinical outcomes, enabling their use to design clinical trials. The ability to identify targets with a causal link to disease and predict clinical outcomes could enable Aitia to address one of the industry's most persistent problems.

The company is partnering with Servier to apply its skills to pancreatic cancer and Parkinson's, using digital twins to find genes that affect clinical outcomes and identify subpopulations that are most likely to respond. Aitia has a strategic agreement that allows it to use Charles River Laboratories (CRL) and Valo's AI-powered Logica in its discovery programs.

The era of AI-powered, hypothesis-free drug discovery and development has arrived, and Aitia is at the forefront of this revolution.

FAQS:

Q: What is Aitia's approach to drug discovery?

A: Aitia uses causal AI and digital twins to discover novel drug targets and biological mechanisms, reverse-engineering the hidden 95% of human biological circuitry.

Q: What is the significance of Aitia's digital twins?

A: Aitia's digital twins allow for accurate simulation of gene and protein knockdowns at the individual patient level, enabling the discovery and genetic validation of drug targets and biological mechanisms.

Q: How has Aitia validated its technology?

A: Aitia has validated its technology via multiple patient cohorts, in vitro and in vivo experiments, and clinical studies, resulting in over 70 peer-reviewed articles and abstracts.

Q: What is Aitia's focus in terms of disease areas?

A: Aitia is focusing on neurodegenerative diseases, with programs in Alzheimer's, Parkinson's, Huntington's, and amyotrophic lateral sclerosis (ALS).

Q: How is Aitia partnering with other companies?

A: Aitia is partnering with companies such as Servier and Charles River Laboratories (CRL) to apply its skills to various disease areas and advance its drug development pipeline.

More Topics :